Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B

Clin Exp Dermatol. 2010 Jun;35(4):e116-9. doi: 10.1111/j.1365-2230.2009.03737.x. Epub 2009 Nov 3.

Abstract

American cutaneous leishmaniasis is an important endemic zoonotic disease in the New World that comprises a spectrum of clinical manifestations. Diffuse cutaneous leishmaniasis (DCL) is a rare form of the disease characterized by antigen-specific immunodeficiency that often presents with multiple disfiguring non-ulcerated confluent nodules or plaques that involve large areas of the skin, resembling lepromatous leprosy. Relapse is invariable in advanced stages, despite aggressive chemotherapy, and a plethora of drugs has been tested with unchanging results. We report on a severe an exceptional case that resolved after treatment with amphotericin B, a drug considered only mildly effective, and discuss the therapeutic approach to this disease.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Amphotericin B / therapeutic use*
  • Antiprotozoal Agents / therapeutic use*
  • Facial Dermatoses / drug therapy
  • Facial Dermatoses / pathology
  • Humans
  • Leishmaniasis, Diffuse Cutaneous / drug therapy*
  • Leishmaniasis, Diffuse Cutaneous / pathology
  • Male

Substances

  • Antiprotozoal Agents
  • Amphotericin B